Comparative analysis of six months formulation of LHRH analogues for prostate cancer treatment;Análisis comparativo entre los análogos de la LHRH de administración semestral en el tratamiento del cáncer de próstata

Archivos Espanoles de Urologia

Volumn 63, Issue 4, 2010, Pages 275-281

  Amo, Felipe Herranz ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Efficacy; LHRH analogue; Prostate cancer; Safety; Semiannual administration

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DRUG DERIVATIVE; GONADORELIN; LEUPRORELIN; TRIPTORELIN;

ARTICLE; COMPARATIVE STUDY; DRUG ADMINISTRATION; HUMAN; MALE; PROSTATE TUMOR; TIME;

ANTINEOPLASTIC AGENTS, HORMONAL; DRUG ADMINISTRATION SCHEDULE; GONADOTROPIN-RELEASING HORMONE; HUMANS; LEUPROLIDE; MALE; PROSTATIC NEOPLASMS; TIME FACTORS; TRIPTORELIN;

EID: 77957825212     PISSN: 00040614     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer Statistics, 209. Ca Cancer J Clin. 2009;59:225-49.
2. Herranz Amo F, Arias Fúnez F, Arrizabalaga Moreno M, Calahorra Fernández FJ, Carballido Rodríguez J, Diz Rodríguez R, et al. El cáncer de próstata en la Comunidad de Madrid en el año 2000. II - Presentación y diagnóstico. Actas Urol Esp, 2003;335-44.
3. Heindenreich A. Bolla A, Joniau S, van der Kwast TH, Matveev V, Mottet MN, et al. Guidelines on prostate cancer. 2009. http://www.uroweb.org/fileadmin/ tx-eauguidelines/2009/Full/Prostate-Cancer.pdf.
4. NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer. v. 2. 2009. www.nccn.org.
5. Barry MJ, Delorenzo MA, Walker-Corkery ES, Lucas FL, Wennberg DC. The rising prevalence of androgen deprivation among older American men since the advent of prostate-specific antigen testing: a population-based cohort study. BJU Int, 2006;98:973-8.
6. Huggins C, Hodges CV. Studies on prostate cancer. Effect of castration, estrogen and androgen injection on serum phosphatases in metastatic carcinoma og the prostate. Cancer Res. 1941. 1:293-7.
7. Lahlou N. Pharmacocinétique et pharmacodynamique de la triptoreline. Ann Urol. 2005. 39: S78-S84.
8. McLeod DG. Hormonal therapy: Historical perspective to future directions. Urology. 2003. 61 (Suppl 2A): 3-7. (Pubitemid 36355870)
9. Crawford ED, Sartor O, Chu F, Perez R, Karlin G, Garrett JS. A 12-month clinical study of LA-2585 (45.0 mg): A new 6-months subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol, 2006;175:533-6. (Pubitemid 43067346)
10. Tunn UW, Wiedey K. Safety and clinical efficacy of a new 6-month depot formulation of leuprolerin acetate in patients with prostate cancer in Europe. Prostate Cancer Prostatic Dis, 2009;12:83-7.
11. Lundstróm EA, Rencken RK, van Wyk JH, Coetzee LJE, Bahlmann JCM, Reif S, et al. Triptorelin 6-months formulation in the management of patients with locally advanced and metastatic prostate cancer. An open-label, non-comparative, multicentre, phase III study Clin Drug Investig, 2009;29:757-65.
12. Oefelein MG, Feng A, Scolieri MJ, Ricchiuti D, Resnick MI. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urol, 2000;56:1021-4.
13. Morote J, Orsola A, Planas J, Trilla E, Raventós CX, Cecchini L, Catalán R. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J Urol, 2007;178(4Pt1): 1290-5. (Pubitemid 47368393)
14. Morote J, Esquena S, Abascal JM, Trilla E, Cecchini L, Raventós CX, Catalán R, Reventós J. Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer. Urol Int, 2006;77:135-8. (Pubitemid 44195773)
15. Sarosdy MF, Schellhammer PF, Soloway MS, Vogelzang NJ, Crawford ED, Presti J, Chodak GW, Mitchell P, Porter L. Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer. BJU Int, 1999;83:801-6. (Pubitemid 29224400)
16. Oefelein MG, Cornum R. Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm. J Urol, 2000;164(3 Pt 1):726-9. (Pubitemid 30637611)
17. Wechsel HW, Zerbib M, Pagano F, Coptcoat MJ. Randomized open labelled comparative study of the efficacy, safety and tolerability of leuprorelin acetate 1M and 3M depot in patients with advanced prostatic cancer. Eur Urol, 1996;30(Suppl 1):7-14. (Pubitemid 26402032)
18. Jocham D. Leuprorelin three-month depot in the treatment of advanced and metastatic prostate cancer: long-term follow-up results. Urol Int, 1998;60(Suppl 2):18-24. (Pubitemid 28187943)
19. Zlotta A, Debruyne FMJ. Expert opinion on optimal testosterone control in prostate cancer. Eur Urol, 2005; (Supple. 4):37-41. (Pubitemid 41423591)
20. Khan MS, ÓBrien A. An evaluation of pharmacokinetics and pharmacodynamics of leuprorelin acetate 3M-depot in patients with advanced and metastatic carcinoma of the prostate. Urol Int, 1998;60:33-40. (Pubitemid 28072437)
21. Fontana D, Mari M, Martinelli A, Boccafoschi C, Magno C, Turriziani M, et al. 3-month formulation of goserelin acetate ('Zoladex' 10.8-mg depot) in advanced prostate cancer: results from an Italian, open, multicenter trial. Urol Int, 2003;70:316-20. (Pubitemid 36566264)
22. *) (Pubitemid 47368393)
23. Michaelson MD, Cotter SE, Gargollo PC, Zietman AL, Dahl DM, Smith MR. Management of complications of prostate cancer treatment. CA Cancer J Clin, 2008;58:196-213.